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Abstract
Introduction: Human mesenchymal stromal cells (MSCs) can be isolated from different sources including bone
marrow and term placenta. These two populations display distinct patterns of proliferation and differentiation in
vitro. Since proliferation and differentiation of cells are modulated by cell–matrix interactions, we investigated the
attachment of MSCs to a set of peptide-coated surfaces and explored their interactions with peptides in
suspension.
Methods: Human MSCs were isolated from bone marrow and term placenta and expanded. Binding of MSCs to
peptides was investigated by a cell-attachment spot assay, by blocking experiments and flow cytometry. The
integrin expression pattern was explored by a transcript array and corroborated by quantitative reverse transcription
polymerase chain reaction and flow cytometry.
Results: Expanded placenta-derived MSCs (pMSCs) attached well to surfaces coated with fibronectin-derived
peptides P7, P15, and P17, whereas bone marrow-derived MSCs (bmMSCs) attached to P7, but barely to P15 and
P17. The binding of bmMSCs and pMSCs to the peptides was mediated by β1 integrins. In suspension, expanded
bmMSCs barely bind to P7, P13, P15, and less to P14 and P17. Ex vivo, bmMSCs failed to bind P7, but displayed a
weak interaction with P13, P14, and P15. In suspension, expanded pMSCs displayed binding to many peptides,
including P4, P7, P13, P14, P15, and P17. The differences observed in binding of bmMSCs and pMSCs to the
peptides were associated with significant differences in expression of integrin α2-, α4-, and α6-chains.
Conclusions: Human bmMSCs and pMSCs show distinct patterns of attachment to defined peptides and maintain
differences in expression of integrins in vitro. Interactions of ex vivo bmMSCs with a given peptide yield different
staining patterns compared to expanded bmMSCs in suspension. Attachment of expanded MSCs to peptides on
surfaces is different from interactions of expanded MSCs with peptides in suspension. Studies designed to
investigate the interactions of human MSCs with peptide-augmented scaffolds or peptides in suspension must
therefore regard these differences in cell–peptide interactions.
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Background
Multipotent mesenchymal stromal cells (MSCs) have
been detected in and isolated from various tissues and
niches. Today the main source for isolation of MSCs is
the bone marrow in the iliac crest or in the femoral shaft
[1, 2]. Closely related mesenchymal cells have been de-
scribed in the white pulp of teeth [3–5] and as pericytes
along the vasculature of adipose tissue [6–9], the endo-
metrial and fetal parts of placenta [10–13], in muscle tis-
sue [14, 15], and in inner organs [16, 17]. Furthermore,
related cells have been isolated from umbilical cord
blood [18] and peripheral blood [19, 20], urine [21], am-
niotic fluid and Wharton’s jelly of the umbilical cord [22,
23], and even from avascular tissue [24, 25]. The niches
for these MSCs or MSC-like cells differ significantly in
their mechanical and chemical composition. Bone mar-
row, for instance, is rather stiff (E ≈ 100 kPa), cartilage is
considerably softer (E ≈ 30 kPa), muscle is quite elastic
(E ≈ 12 kPa), and adipose tissue very flexible (E <10 kPa)
[26]. Moreover, in bone marrow, type I, III, V and VI
collagen, laminin isoforms containing the α4-, and α5-
chains, fibronectin, and glycosaminoglycans dominate
the stem cell niche [27–31], whereas pericytes of pla-
centa are found in contact with laminin α2- and α5-
chains and type IV collagen of the basal lamina and adja-
cent to fibronectin [32].
The MSCs from bone marrow (bmMSCs) express a
significantly different transcriptome compared to MSCs
from pancreas or placenta [16, 33]. Human bmMSCs
differ in their growth kinetics and expression of integrin
α4 from placenta-derived MSCs (pMSCs) [34]. More-
over, MSCs from adipose tissue express CD34 [35, 36],
an antigen not found on bmMSCs [37–39]. Our recent
studies are in line with these reports as we find signifi-
cant differences between bmMSCs and pMSCs in their
osteogenic differentiation capacities [40], expression of
Runx2, WISP2, osteoglycin and osteomodulin [33], and
expression of the stem cell markers alkaline phosphatase
and CD146 [13].
Previously we investigated the binding and attachment
of bmMSCs to proteins and peptides in comparison to
fibroblasts [41]. There, fibroblasts differed from bmMSCs
in both binding, as determined by the multiple substrate
array technique [42], and short-term attachment [30].
Based on the fact that bmMSCs and pMSCs differed in
their proliferation and differentiation capacities [13, 33, 34],
and proliferation and differentiation of MSCs are modu-
lated by the extracellular matrix and integrin signaling
[43–50], we investigated the interaction of bmMSCs ver-
sus pMSCs with a set of peptides and the expression of
integrins in more detail.
Our results suggest that i) bmMSCs and pMSCs differ
significantly in their expression of integrins, and there-
fore in attachment to distinct peptides. In addition, ii)
interactions of MSCs with peptides on a solid phase via
attachment follow different kinetics or thermodynamics
compared to interactions of MSCs with the same peptides
in suspension, and iii) the expression of matrix-binding re-
ceptors on bmMSCs ex vivo seems be modulated by the
in vitro culture condition. This may have interesting conse-
quences when, for instance, attachment assays are per-
formed in vitro to investigate the mobilization and migration
of MSCs in the circulation and homing to specific niches.
Methods
Preparation of MSCs from femoral bone marrow and term
placenta tissue
Aspirates from human femoral bone marrow (n = 15 pa-
tients, nine females, six males, mean age 67 years, aver-
age volume 12–15 mL) were obtained from the Clinic
for Trauma and Restorative Surgery, BG Trauma Center
Tübingen, University of Tübingen, after written and in-
formed consent. The fraction of mononuclear cells was
enriched by density gradient centrifugation and the cells
were expanded as described recently [51]. Human term
placenta was obtained from the Department of Gynecology
and Obstetrics, University of Tübingen Hospital, from
mothers undergoing planned Caesarean delivery after writ-
ten and informed consent (n > 15 donors, mean age
34 years). The MSCs were isolated, purified and cultured
in a good manufacturing practice (GMP)-compliant expan-
sion medium as described recently [51]. Both types of
MSCs were characterized according to the criteria defined
by the International Society for Cellular Therapy by flow
cytometry to confirm the expression of CD73, CD90,
CD105, and CD146 as well as documenting lack or very
low expression of CD11b or CD14, CD34, and CD45
(not shown) [33, 37, 40, 52]. The differentiation capaci-
ties of the MSCs investigated were confirmed in vitro by
induction of osteogenic, adipogenic, and chondrogenic
(bmMSCs), or adipogenic and chondrogenic differenti-
ation (pMSCs), respectively [1] (not shown). Dermal fi-
broblasts were isolated from surgical waste from the
skin of patients and expanded as described (n = 4, [41]).
In some experiments MSCs were washed (2 × phos-
phate-buffered saline (PBS)) detached by mild proteoly-
sis (5 min, 37 °C, Accutase®, PAA Laboratories), washed
again, counted, and aliquots of 5 × 105 viable MSCs
were resuspended in 1 mL cold freezing medium
(Dulbecco's modified Eagle's medium, 20 % fetal bovine
serum (FBS), 10 % dimethyl sulfoxide), cooled further
and stored in the gas phase of liquid N2 tanks. For add-
itional studies, frozen aliquots of MSCs were rapidly
thawed, washed twice with 25 mL medium, seeded in
culture vessels, and cultured over night in GMP-
compliant expansion medium. Then the cells were
washed twice with PBS, detached by proteolysis (5 min,
37 °C, Accutase®), counted to confirm yield and
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viability, and utilized for the corresponding experiment.
The study was approved by the Ethics Committee of
the Medical Faculty of University of Tübingen (# 453/
2011B02).
Attachment of MSCs to proteins and peptides
Attachment of MSCs or fibroblasts to proteins and pep-
tides immobilized on plastic surfaces was explored as
described previously [30, 53, 54]. As substratum for cell
attachment, bovine serum albumin (BSA) was activated
by maleimide-ester, coupled with peptides, and separated
from residual peptides by dialysis and gel filtration [41].
The peptide-modified BSA served as substrate for the
cell attachment assays. Then cells were harvested as de-
scribed above, viability was confirmed (>90 %, trypan
blue dye exclusion) and 3 × 106 cells were resuspended
in 1.3 mL medium supplemented with 0.1 % PSA buffer
(final concentration 0.9 % BSA/PSA) and ion-mix (final
concentration 1 mM CaCl2,1 mM MgCl2, 0.025 mM
MnCl2); 200 μL of this cell suspension was added to the
substratum spots. After incubation at ambient temperature
for 15 min, attachment of the cells was analyzed by mi-
croscopy. Cells not adhering to the spots were removed by
washing (4 × PBS), and the cells attached recorded by
dark-field and phase-contrast optics (Leica DM IRB, Leica
Wetzlar Germany). Attachment of cells to laminin-111
(LM), fibronectin (FN) or BSA (all from Sigma-Aldrich)
served as controls, respectively.
In a second line of experiments, attachment of MSCs
to peptides or proteins was blocked by pre-incubation of
5 × 105 MSCs per spot in 100 μL media with a function
blocking monoclonal antibody (mAb) to human β1 in-
tegrin (anti-CD29, clone: 4B4, dilution 1:20, 4 °C for
30 min; Beckman Coulter Inc, USA). MSCs incubated
with mAb to CD90 (clone: Thy1-A1, dilution 1:5, 4 °C
for 30 min; R&D Systems) and mock-treated MSCs
served as controls. Then the cells were added to the sub-
stratum spots, incubated, washed and recorded as de-
scribed above.
To label cells by fluorescent dyes, 1 × 106 cells in the
second passage of in vitro culture were detached by mild
proteolysis (5 min, 37 °C, Accutase®), washed twice with
PBS and incubated with PKH26 (red label) or PKH67
(green label) as described [55] using standard reagent
kits (Sigma-Aldrich, Taufkirchen, Germany). To confirm
high viability of MSCs in the attachment assays, cells
were loaded with Calcein-AM and Ethidium-homodimer
(Live/Dead cell Staining Kit II, PromoCell, Heidelberg,
Germany). Then attachment of cells was explored with
the labeled MSCs as described above. Live cells emitting
green fluorescence at 515 nm and dead cells emitting
red fluorescence at 620 nm were recorded by a fluores-
cence microscope.
Flow cytometry of MSCs after expansion in vitro and ex
vivo
MSCs were expanded to the second passage, harvested
as described above, collected in medium and washed
with PBS to determine the cellular yield and viability in
a hematocytometer by trypan dye exclusion. Cells (5 × 105)
were resuspended in fluorescence-activated cell sorting
(FACS) buffer (500 mL PBS, 10 mL FBS, 0.5 % (w/v) NaN3,
372 mg ethylenediaminetetraacetic acid) and incubated on
ice for 30 min with mAbs to different antigens at appro-
priate dilutions (Table 1). Then, the cells were washed
twice, resuspended in FACS buffer again and explored by
flow cytometry as described recently [52]. To test
bmMSCs and pMSCs for peptide interactions, serial dilu-
tions of fluorescein isothiocyanate (FITC)-labeled peptides
(Table 2) were resuspended in FACS buffer and staining of
MSCs was explored by flow cytometry as described above.
Unstained MSCs and CompBeads (BD Biosciences, Hei-
delberg, Germany) served as controls [52]. To this end the
CompBeads were resuspended in 200 μL FACS buffer for
automatic compensation with the BD FACS Diva acquisi-
tion program (BD Biosciences). Data were processed and
analyzed using FACS Diva and FlowJo 7.2.2 (Treestar Inc,
Ashland, OR, USA) following recent guidelines [56]. Flow
cytometry data were computed as geometric means of
fluorescence intensity (MFI).
In other experiments cells were prepared ex vivo from
fresh samples of bone marrow by Ficoll® gradient centri-
fugation [51], washed, counted and directly stained with
fluorescently labeled mAb to the MSC-specific antigen
CD271 as described recently [38] (Table 1). Then, the
cells were washed twice with FACS buffer and resus-
pended in FACS buffer with the diluted labeled peptides
(Table 2), and incubated on ice. The bmMSCs were
washed twice again and subjected to flow cytometry.
Double labeled cells were analyzed in the dot blot mode
with four quadrants. Unstained cells and cells incubated
with anti-CD271 only served as controls and to set the
gates.
Differences in transcripts encoding integrins
To explore the differences in the expression of integrins
between bmMSC and pMSC two data sets generated by
gene array using the Affymetrix GeneChip technology
were employed in this study as described recently [33].
Transcripts encoding integrins that were expressed sig-
nificantly different in bmMSC versus pMSC were inves-
tigated further by quantitative reverse transcription
polymerase chain reaction (qRT-PCR).
qPCR of transcripts after reverse transcription
To enumerate the steady state mRNA expression in
bmMSCs versus pMSCs, cells were harvested by Accu-
tase® (PAA) and washed by cold PBS; 1 × 106 MSCs were
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collected in 1.5 mL microtubes and mRNA was ex-
tracted (RNeasy, Qiagen, Hilden Germany). Reverse
transcription was performed from 1 μg of total RNA
(oligo-(dT)npriming, Advantage RT for PCR Kit, Clon-
tech, Mountain View, USA) to generate the cDNA sub-
strate for PCR. Gene-specific cDNA was enumerated by
qRT-PCR (LightCycler, Roche, Mannheim, Germany)
[57] using transcript-specific primers (MWG Eurofins,
Ebersberg, Germany). Quantification of transcripts en-
coding GAPDH and PPIA served as references in each
of the amplifications to normalize the amounts of the
target gene by the FitPoint (ΔΔCt–) method [57]. The
mean values of replicate experiments and standard devi-
ations were calculated by Excel® spread sheet software,
and statistical significances between groups of data were
computed with a two-sided paired Student’s t-test.
Probability values (p) equal to or less than 0.05 were
considered to be statistically significant.
Results
Attachment of human MSCs to proteins and peptides
Human bmMSCs and pMSCs were isolated, expanded
and characterized to meet the International Society for
Cellular Therapy criteria [37]. Second passage MSCs
were harvested and added to peptide-coated dishes to
compare their attachment to peptides in comparison to
proteins (Fig. 1). Patterns of attachment of human
bmMSCs and pMSCs differed considerably. While both
types of MSCs attached well to LM-111 (all = 100 %), FN
(all = 100 %), and the LM α4-chain-derived peptide P14
(≥80 %), most pMSCs attached well to FN-derived peptides
P15 (80 %) and P17 (90 %), but only a few bmMSCs (20 %
and 7 %, respectively) attached to peptides P15 or P17
(Fig. 2). Neither bmMSCs, pMSCs, nor dermal fibroblasts
(DF) attached to peptides P2, P4, P13, P16, or to albumin
(Fig. 2). The pMSCs and DF attached rather well to peptide
P17 (Figs. 1 and 2). Peptide P16 is a part of P17 (Tables 1
and 2), but neither MSCs nor DF attached to P16 suggest-
ing that this interaction between the cells and peptides is
highly selective. Peptides P7, P15 and P17 are three differ-
ent peptides derived from FN. The pMSCs preferably
bound to P15 (80 %) and P17 (90 %) when compared to
bmMSCs (20 % and 7 %; Fig. 2, Table 3). In contrast, about
40 % of both pMSCs and bmMSCs bound to FN-derived
peptide P7. This suggested that MSCs isolated from differ-
ent tissues express distinct patterns of receptors which
Table 1 List of reagents employed: monclonal antibodies for exploring mesenchymal stromal cells by flow cytometry
CD Isotype Clone Label Source Company Dilution
CD14 IgG2A MφP9 FITC Mouse R&D Systems 1:5
CD34 IgG1 4H11 PE Mouse BioLegend 1:10
CD45 IgG1 MEM-28 PE Mouse BioLegend 1:5
CD73 IgG1 AD2 PE Mouse BD Bioscience 1:2.5
CD90 IgG2A Thy1-A1 PE Mouse R&D Systems 1:5
CD105 IgG1 SN6 AF 488 Mouse ABD Serotec 1:5
CD 271 IgG1 ME20.4-1.H4 APC/AF 647 Mouse Miltenyi Biotec 1:5
CD29 / ITGB1 IgG1 MAR4 BV510 Mouse BD Bioscience 1:10
CD49b / ITGA2 IgG2A 12 F1 PE-CF594 Mouse BD Bioscience 1:10
CD49d / ITGA4 IgG1 9 F10 BB515 Mouse BD Bioscience 1.10
CD49f / ITGA6 IgG2A GoH3 PE-CF594 Rat BD Bioscience 1:10
ITGA7 Polyclonal serum ø FITC Rabbit Biorbyt 1:10
Table 2 List of reagents employed: peptides
Peptide code Amino acid sequence Estimated molecular weight Origin
2 GEFYF DLRLK GDK 1585 Da Human collagen IV α1 chain
4 LAIKN DNLVY VY 1421 Da Human laminin α4 chain G domain
7 WQPPR ARITG Y 1344 Da Human fibronectin
13 AASIK AVAVS ADR 1257 Da Human laminin α1
14 DVISL YNFKH IY 1509 Da Human laminin α4 chain G domain
15 KREDV Y 808 Da Synthetic peptide
16 EILDV (part of P17) 600 Da Human fibronectin type III repeat
17 DELPQ LVTLP HPNLH GPEIL DVPST 2726 Da Human fibronectin type III repeat
Maerz et al. Stem Cell Research & Therapy  (2016) 7:29 Page 4 of 14
Fig. 1 Attachment assay with human MSCs. Human MSCs from bone marrow (a) and term placenta (b) were incubated on spots coated with
peptides P2–P17, laminin-111 (LM), or fibronectin (FN) as indicated. After 15 min of incubation non-adherent cells were washed away and MSCs
attached are visualized by microphotography. Spots coated with activated bovine serum albumin (aBSA) served as controls
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interact with defined epitopes or peptides derived from
extracellular matrix proteins.
In addition, we investigated the attachment of MSCs
to peptides P7, P14, P15, and P17 that facilitated suffi-
cient binding of cells prior to deep freezing (naïve) and
after cryopreservation (cryo) and revitalization (Fig. 2b).
In all cases, attachment of cryopreserved bmMSCs and
pMSCs was lower compared to the same cells prior to
deep freezing, but it was not different in bmMSC com-
pared to pMSC (p = 0.64). The mean normalized attach-
ment of naïve MSC dropped 2.2-fold from 43 ± 18 % to
19.2 ± 14.2 % (n = 10, p ≤ 0.0048; Fig. 2b), suggesting that
cryopreservation strongly influences the interaction be-
tween cells and the extracellular matrix.
To investigate the nature of the interactions between
the human MSCs and the proteins or peptides, respect-
ively, the cells were saturated with a function blocking
mAb against the integrin β1 chain and then attachment
to the MSCs binding proteins and peptides was explored
(Fig. 3). Pre-incubation of the cells with a mAb to integ-
rin β1 chain (i.e., anti-CD29) blocked the interaction be-
tween the bmMSCs and the substratum completely
whereas pre-incubation of bmMSCs with an unrelated
mAb (i.e., anti-CD90) did not interfere with their attach-
ment (Fig. 3a). In analogy, pre-incubation of pMSCs
with a mAb to the integrin β1 chain blocked attachment
of the cells to FN and peptides P15 and P17 (Fig. 3b).
To test if MSCs attached to maleimide ester-activated
BSA in an unspecific manner, unmodified BSA and acti-
vated BSA were spotted onto glass slides and incubated
with pMSCs. Binding of MSCs to activated BSA was not
observed (Fig. 3b). This corroborated that the attach-
ment patterns were generated by cell-to-peptide or cell-
to-protein interactions and not by chemical binding of
the cells to the remaining maleimide ester groups on ac-
tivated BSA. To further confirm the specificity of the
cell–substratum interaction, we incubated red labeled
MSCs on FN or mixed green labeled DF with red labeled
bmMSCs to compete for binding sites. Labeling bmMSC
by PKH26 did not interfere with their attachment. The
“green” fibroblasts reduced binding of the “red” MSCs in
part (Fig. 3c). In other experiments the MSCs were la-
beled with Calcein-AM and Ethidium homodimer to
stain viable and dead cells, respectively. The cells at-
tached to LM-111 appeared green and only very few red
nuclei were detected indicating a high viability of the
MSCs employed in the attachment assays (Fig. 3d). We
conclude that the distinct attachment patterns investi-
gated in this study are mediated mainly by cell–peptide
or cell–protein interactions involving β1 integrins.
Interaction of human MSCs with peptides in suspension
In general, MSCs are attached in vivo and in vitro to the
extracellular matrix, to neighboring cells or another
Fig. 2 Overview on attachment patterns of human mesenchymal
stromal cells (MSCs). a Human bmMSCs (n = 14 donors, black bars) or
pMSCs (n = 10 donors, grey bars) were expanded to investigate their
attachment to peptides P2–P17 as indicated. Attachment of MSCs to
laminin-111 (LM) and fibronectin (FN) served as positive control
(100 %), attachment to activated bovine serum albumin (aBSA)
served as negative control (0 %). Attachment of human DF to the
same substratum was tested in comparison to the MSCs (n = 5
donors, hatched bars). b Attachment of primary culture human MSCs
to peptides P7, P14, P15, and P17 was tested prior to deep freezing
(naïve MSCs) and compared to the same cells after cryopreservation
and revitalization (cryo MSCs). Overall, naïve MSCs attached to the
peptides at 43 ± 18 % mean efficacy compared to FN (=100 %).
Cryopreservation caused a reduced overall attachment to these
peptides of all MSCs investigated (19.2 ± 14.2 %). Thus, cryopreservation
yielded a significant drop of attachment of human MSCs (n = 10, mean
reduction 0.42 ± 0.20, p≤ 0.0048)
Table 3 Comparison of cells attaching to peptides and proteins
P2 P4 P7 P13 P14 P15 P16 P17 LM FN aBSA
bmMSC 0 0 42.8 0 84.5 20 0 7.1 100 100 0
pMSC 0 0 40 0 80 80 0 90 100 100 0
DF 0 0 0 0 80 19 0 90 100 100 0
Cells (bone marrow-derived mesenchymal stromal cells (bmMSC) from 14
donors, term placenta-derived mesenchymal stromal cells (pMSC) from 10
donors, dermal fibroblasts (DF) from 5 donors) were added to peptide-coated
spots as listed, incubated for 15 min. and floating cells were washed away. The
numbers in this table present the percentage of cell types attaching to a given
peptide or protein. All cells attached well to laminin 111 (LM) and fibronectin
(FN). They therefore served as positive controls (100 %). Attachment to activated
bovine serum albumin (aBSA) was not observed and therefore served as negative
control (0 %)
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substratum. However, MSCs have also been detected in
suspension in blood [18–20] and umbilical cord blood
[58] and their numbers can be elevated in blood by hyp-
oxia [59, 60]. They can be mobilized under stress condi-
tions [61], but also engraft after intravenous injection
functionally to the bone marrow [62]. This has been
taken as evidence that MSCs may circulate in the blood
and also home to their niche(s). We therefore also inves-
tigated the binding of peptides to expanded bmMSCs
and pMSCs in suspension (Fig. 4). Binding of peptide P4
to bmMSCs was not observed in suspension. The peptides
P7, P13, P14, P15, and P17 showed some binding to
Fig. 3 Contribution of integrins to protein- and peptide- dependent cell attachment. Human bmMSCs (a) or pMSCs (b) were pre-incubated with a
function-blocking antibody to CD29 (integrin β1 chain) or remained untreated as indicated (ø). The cells were then incubated on peptide- or fibronectin
(FN)-coated spots. Pre-incubation of bmMSCs (a) or pMSCs (b) with anti-CD29 mAb completely blocked the attachment of the cells, whereas untreated
MSCs attached well to peptides or proteins. Pre-incubation of bmMSCs with anti-CD90 mAb failed to block attachment of the cells confirming the
specificity of the blocking reaction (a, upper right). Incubation of pMSCs on activated bovine serum albumin (aBSA) did not cause unspecific binding
of cells to this reagent (b). Human bmMSCs were labeled with PKH26 and attachment of PKH26-loaded cells to FN was confirmed (c, left). Human
fibroblasts were labeled with PKH67, mixed 1:1 with PKH26-labeled MSCs and incubated on fibronectin (c, right). DF competed for binding sites and
displaced the MSCs (c, right). Human bmMSCs were loaded with Calcein-AM and EthD-1 to discriminate viable cells (green cytoplasm, v) from dead
cells (red nuclei, d) and added to LM-111-coated spots (d). The MSCs attached presented a bright green fluorescence indicating a high viability of the
population studied (d, v). Only a few dead cells were observed (d, d)
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bmMSC in suspension, but the signal intensities recorded
by flow cytometry (Fig. 4a) did not correlate with the at-
tachment patterns observed (Fig. 2). In contrast to
bmMSCs, all peptides stained pMSCs in suspension, and
with P13, P14 and P17 pMSCs two distinct CD73pos sub-
sets were resolved (Fig. 4b). Depending on the protocol
employed for isolation of MSCs from term placenta, the
cell culture contains a blend of maternal and fetal MSCs
and possibly smaller populations of other mesenchymal
cells such a vascular smooth muscle cells. This may explain
in part the differences in expression of CD73 in the pMSCs
observed (Fig. 4b). Moreover, as seen with bmMSC, pMSC
did not attach to the P13-coated surface (Fig. 1) but pMSC
in suspension were stained with PE-labeled peptide P13
(Fig. 4b). This confirmed that bmMSCs and pMSCs display
distinct interaction patterns with peptides. At the same
time the results indicated that interactions of MSCs with
peptides are variable when in suspension (Fig. 4) compared
to interactions of the cells on a solid phase (Figs. 1, 2, 3).
Interactions of peptides with bmMSCs ex vivo
Expression of cell surface proteins may be regulated by
in vitro cell culture conditions. We therefore explored
the binding of peptides to bmMSCs ex vivo (Fig. 5) in
comparison to bmMSCs after expansion in vitro (Fig. 4).
To discriminate bmMSCs from other cells in samples of
human bone marrow ex vivo, the bmMSCs were labeled
by a mAb to CD271 as described recently [38]. All
peptides employed yielded at least some binding to mono-
nuclear cells from human bone marrow by staining 1.5 %
to 20 % of the CD271neg population (Fig. 5, n = 3). Pep-
tides P4, P13, P14, and P15 stained very few CD271pos
cells (about 0.2–0.5 % of all cells), whereas peptides P7
and P17 failed to bind to CD271pos bone marrow-derived
cells ex vivo (Fig. 5). This indicated that the expression of
extracellular matrix receptors on MSCs is modified by the
culture conditions utilized to expand the cells.
Expression of integrins in bmMSCs and pMSCs in vitro
Beta-1 integrins mediate the attachment of human
MSCs to the proteins and peptides investigated in this
study (Fig. 3). We therefore investigated the transcrip-
tome of these populations to explore differences in the
expression of integrins by gene array (Table 4). By this
method the transcript amounts encoding collagen- and
thrombospondin-binding integrin chain α2(β1), FN-
binding integrin chain α4(β1) or α4(β7) and LM-binding
integrin α6(β1) were significantly lower in bmMSCs com-
pared to pMSCs, whereas transcripts of integrin chains
α7(β1) and α11(β1) were higher in bmMSCs (p < 0.05).
The differences in gene expression were confirmed by
qRT-PCR with RNA extracted from MSCs of other do-
nors. In bmMSCs integrin chains α2 (5.4-fold, statisti-
cally not significant) α4 (2-fold, p < 0.0006) and α6
(3.3-fold, p < 0.005) were expressed at a lower level,
and integrin chains α7 (145-fold, p < 0.0001) and α11
Fig. 4 Interaction of peptides with human MSCs in suspension. Human bmMSCs (a) and pMSCs (b) were expanded to the second passage of in
vitro culture, harvested by mild proteolysis, and stained with titrated amounts of FITC-labeled peptides. In addition, bmMSCs were counterstained with
PE-labeled anti-CD90 (a), and pMSCs with PE-labeled anti-CD73 (b) to confirm their mesenchymal origin. Moderate binding of peptides P7, P13, and
P15 was observed on bmMSCs (a). In contrast, pMSCs displayed a bright staining with all peptides investigated (b). FITC Fluorescein isothiocyanate, FSC
Forward scatter, PE Phycoerythrin, SSC Side scatter
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(4.8-fold, p < 0.41, statistically not significant) were
expressed at a higher level in bmMSCs compared to
pMSCs (Table 4). We hypothesized that the differences in
expression of integrin heterodimers contributed to the
preferred in vitro attachment of pMSCs to peptides P15
and P17 when compared to bmMSCs (Fig. 2). We there-
fore explored the expression of integrin α-chains on
bmMSCs and pMSCs by flow cytometry (Fig. 6). The ex-
pression of the integrin α2-, α4-, α6-, and β1-chains was
lower on bmMSCs compared to pMSC whereas expres-
sion of integrin α7 revealed no differences in staining in-
tensities (Fig. 6). This corroborated at the protein level the
differences in expression of the integrin α2-, α4-, and α6-
chains between human bmMSCs and pMSCs as observed
on transcript levels by gene array and qRT-PCR (Gene
Array data are available online, see Additional file 1).
Discussion
Our study provided evidence that MSCs can bind to
small peptides in a specific way through integrins, that
Fig. 5 Interaction of peptides with human bmMSCs ex vivo. Mononuclear cells were purified from human bone marrow by Ficoll® gradient
centrifugation, washed and incubated with peptides as indicated and counterstained with AF-647-labeled mAb to CD271, a marker for bmMSCs.
Peptide P13 stained a small subset of CD271pos bone marrow cells ex vivo, whereas peptides P4, P14, and P15 stained only very few CD271pos
cells. Peptides P7 failed to bind to CD271pos cells, but all peptides interacted with CD271neg bone marrow cells. FITC Fluorescein isothiocyanate,
FSC Forward scatter, SSC Side scatter
Table 4 Expression of integrins in human MSCs in vitro
Transcript Gene array (CFC) R-NTR
ITGA2 −2.5 (p < 0.05) 5.4-fold (p = 0.063, s.n.s.)
ITGA4 −12.4 (p < 0.0001) 2-fold (p < 0.0006)
ITGA6 −19.3 (p < 0.0001) 3.3-fold (p < 0.005)
ITGA7 +6.8 (p < 0.0001) 0.007-fold (p < 0.0001)
ITGA11 +4.6 (p < 0.0006) 0.2-fold (p < 0.41, s.n.s.)
The table documents the differences in integrin transcript expression between
bone marrow-derived mesenchymal stromal cells (bmMSCs) and term
placenta-derived mesenchymal stromal cells (pMSCs) as evaluated by gene
array (CFC; left, n ≥ 6 RNA samples each) or quantitative reverse transcription
polymerase chain reaction (R-NTRs; right, n ≥ 4 cDNA samples each). CFC-values
v > 1 denominate a higher, values v < 1 a lower expression in bmMSCs, respectively
(CFC: combined fold change of transcripts enumerated by gene array,
after evaluation with FDR corrections). R-NTR ratio of normalized transcript
rates, s.n.s. statistically not significant
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patterns of MSC–peptide interactions depend on the
type of MSCs investigated, and that such interactions
are modified by cell culture conditions. In addition, the
attachment of cells to peptide-augmented surfaces dif-
fers from the patterns of staining of MSCs in suspension.
Integrins are important receptors for anchoring cells in
a tissue. They play an important role in pattern forma-
tion, tissue organization, differentiation, mobilization
and homing of cells and many other physiological and
pathological processes [48, 49, 63–66]. The composition
of the extracellular matrix in a given tissue and even
more in a (stem) cell niche is important to maintain the
integrity of the tissue and at the same time its function
[27, 67]. By choice of peptides such a niche or environ-
ment can possibly be mimicked on or in scaffolds to fa-
cilitate the homing or seeding of distinct cells in an in
vivo situation.
We also provide evidence that fibroblasts, bmMSCs
and pMSCs will attach to biomaterials modified with
specific peptides in an ordered way. Therefore two- or
even three-dimensional patterns of different cells and
even closely related cells can be generated in vitro by
modification of the scaffolds' surfaces with peptides.
Blocking β1-integrins by a mAb abolished the attach-
ment of the MSCs to both proteins and peptides. This
confirmed that the peptide–cell interactions investigated
in this study are highly selective and depend on β1-
integrins.
However, the interaction of peptides with integrins
yielded a higher dissociation constant KD compared to
the KD measured for a naïve protein [68]. The RGD pep-
tide–a popular motif used in many attachment assays–
bound with a more than 50-fold lower affinity to its re-
ceptor (KD = 1.7) compared, for instance, to fibrin, the
prototype protein containing the RGD motif [68]. More-
over, attachment of cells to peptides by integrins de-
pends not only on the avidity of the individual ligand
(i.e., peptide/protein)–receptor (i.e., integrin) interaction,
Fig. 6 Detection of integrins on bmMSCs and pMSCs. Human bmMSCs (a) or pMSCs (b) were expanded to the second passage to investigate
the expression of integrin α2, α4, α6, α7, and β1 by flow cytometry. Expression of integrin α2, α4, α6, and β1 was lower on bmMSCs compared to
pMSCs (solid histograms). MSCs incubated with PE-labeled anti-Ig antibody served as control (dotted histograms). For integrin α7, no difference in
expression levels was observed by flow cytometry. PE Phycoerythrin
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but also on the blend of different integrins and expres-
sion level of integrins on a given cell surface. Therefore,
in the context of regenerative medicine or tissue engin-
eering, a selectivity of peptide-modified scaffolds means
a lower affinity of such a scaffold to the cell when com-
pared to protein-coated surfaces. This can possibly be
compensated for by distributing or patterning the pep-
tides on scaffold surfaces according to the density of
integrins on the cells [69]. Then cooperative effects will
“glue” the cells to the scaffold.
As shown in one of our recent studies, expression of
integrins on human MSCs is regulated by transforming
growth factor beta (TGF-β) [53]. Others reported on the
role of platelet-derived growth factor (PDGF), basic
fibroblast growth factor (bFGF) and epidermal growth
factor in regulation of integrins on MSCs or other cells
[70–72]. These cytokines are found in the sera used to
complement the growth medium for human MSCs [51],
and their titers in media may differ from the concentra-
tions recorded in situ. Therefore, expression of integrins
on cells may differ in vivo compared to in vitro. We used
GMP-compliant media enriched with human plasma
and platelet extract for expansion of MSCs to keep our
preclinical experiments close to a future clinical applica-
tion [51]. Human platelet extract is a rich source for
PDGF, TGF-β, bFGF and other factors [73]. This ex-
plains in part the differences observed in peptide binding
between MSCs ex vivo and MSCs after expansion. This
finding also suggests that binding assays performed with
MSCs expanded in media containing xenobiotic serum
cannot completely reflect the interaction of MSCs in
situ. This problem applies to MSC-specific antigens used
for ex vivo staining as well since expression of CD271
on human bmMSCs was elevated on cells ex vivo, but
disappeared in primary cultured cells [13, 38]. Compar-
ably, expression of CD34 on adipose tissue-derived hu-
man MSCs varies and depends on the cell culture
conditions [7]. In addition, the concentration of growth
factors detected in serum depends on the age of the
donor [74]. Therefore, not only MSC proliferation, but
also integrin expression, will depend on the quality of
platelet extract used to enrich the MSC media. Expres-
sion of integrins on MSCs may change during in vitro
culture and expression of integrin α6 chain was lost on
human umbilical cord-derived MSCs after 5 passages ex-
pansion [75]. We used bmMSCs and pMSCs in their
second passage of culture. Therefore loss of integrins on
bmMSCs due to extended expansion in this time frame
is not a likely event. A recent study on expression of
integrins on human bmMSCs reported minimal or no
detection of integrin α6, but intermediate to high ex-
pression of other integrins [76]. In contrast, we find
some expression of integrin α6 chain on bmMSCs in our
experiments. This seemingly conflict of results may be
caused by the differences in preparation and mainten-
ance of the bmMSCs since we used—unless specified
differently—non-cryopreserved MSCs expanded in GMP-
compliant medium for two passages. Danmark and col-
leagues used a commercial source for bmMSCs and
therefore cryopreserved cells, and a commercial MSC
medium of undisclosed composition [76]. Our data sug-
gest that cryopreservation significantly reduced attach-
ment of MSCs to peptides. These important differences
in the experimental design may account for the different
outcomes.
Moreover, short-term attachment of MSCs to surfaces
is modulated in vitro by proteins found in the cell cul-
ture medium used. This is relevant when MSCs are in
contact with surfaces that contain physiological ligands
for high-affinity attachment of cells, such as RGD pep-
tides. Biodegradable polymers such as lactate esters are
widely used compounds for tissue engineering that do
not contain natural cell binding motifs. Attachment of
cells to such polymers depends therefore on the adsorp-
tion versus desorption of peptides or proteins to the
polymer to which the cells then subsequently bind in the
second place [77]. However, long-term binding of MSCs
to any substratum in vitro and in vivo is not only modi-
fied by the composition of the pericellular milieu, but in
addition modulated by proteins and extracellular matrix
components produced by the MSCs themselves. For in-
stance, integrin α5β3- and αvβ3-mediated binding of
MSCs to FN triggers migration of the cells through
PDGF-BB and PDGF-R signaling [70]. Binding of MSCs
to FN or fibrin modulated their osteogenic differentiation
in two- and three-dimensional cultures [78]. Laminin-322
modulated osteogenesis of MSCs [45], whereas type II col-
lagen hydrogels together with TGFβ1 promoted chondro-
genesis [79]. Our preliminary data suggest that pMSCs
express, at least on a transcript level, less LAMA5,
COL4A5 and COL13A1, but more COL5A3, COL14A1
and COL11A1 than bmMSCs. These differences in ex-
pression of extracellular matrix proteins by bmMSCs ver-
sus pMSCs add to the integrin-mediated differences
discussed above by occupying the binding sites of their re-
spective integrins. Moreover, MSCs also produce cyto-
kines and growth factors including TGFβ1 thus modifying
expression and conformation of integrins in an autocrine
way [36, 53]. Therefore dissimilarities reported for attach-
ment, migration, proliferation or differentiation of MSCs
in different studies can be explained by the inconsistencies
in the various protocols employed [45, 46, 48].
Covering β1 integrins on MSCs by a mAb blocked
their migration to an infarcted heart [80], and others
provided evidence for integrin α4 receptors in the con-
text of MSC homing [81]. Expression of integrins differs
between stromal cells from bone marrow and adipose
tissue [36]. Our data complement these studies as we
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find differences in cell–peptide interactions observed be-
tween bmMSCs and pMSCs in vitro and between
bmMSCs ex vivo and in vitro, and add to the evidence
for the role of integrins in tissue and/or niche-specific
homing of these cells.
Conclusion
In summary, human MSCs derived from bone marrow
or placenta maintain distinct differences in expression of
integrins after expansion in fully GMP-compliant medium
for at least two passages of in vitro culture. bmMSCs dis-
play differences in peptide binding ex vivo compared to
bmMSCs in vitro. We conclude that studies investigating
the interaction of MSCs with peptides are biased by the
growth conditions utilized, and even GMP-compliant
media enriched with human plasma and platelet extract
do not reflect the milieu a MSC is exposed to in bone
marrow or in other tissues in vivo. Studies involving
peptide-augmented scaffolds designed for in vivo applica-
tions must take these differences in MSC–peptide interac-
tions into account.
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